GLYCOSTEM THERAPEUTICS
Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company focused on developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK-cells are the body’s first line of defence because of the innate ability of NK-cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally-infected cells. Glycostem’s lead product, oNKord® , is produced in a closed system in Glycostem’s ... state-of-theart production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK-cells for clinical applications. oNKord® successfully concluded phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market.
GLYCOSTEM THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2007-01-01
Address:
Oss, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.glycostem.com
Total Employee:
11+
Status:
Active
Contact:
+31 (0) 412 211 001
Email Addresses:
[email protected]
Technology used in webpage:
Google Maps ReCAPTCHA V2 3 To 9 CcTLD Redirects
Current Employees Featured
Founder
Official Site Inspections
http://www.glycostem.com Semrush global rank: 6.83 M Semrush visits lastest month: 755
- Host name: vip.reactonline.nl
- IP address: 87.233.157.142
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Glycostem Therapeutics"
Investor - glycostem
Our organization is guided by a highly experienced Management Team and Board of Directors and supported by a Scientific Advisory Board that includes renowned experts in the field of innovative cancer therapeutics. Moreover, …See details»
Glycostem Therapeutics - Crunchbase Company Profile & Funding
Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and …See details»
Taking cellular immunotherapy to the next level - glycostem
Glycostem signs global CAR-NK product co-development deal 11th Sep ’19 Glycostem out-license oNKord® for Korea and Japan 9th Sep ’19 Glycostem raises €14 million in equity Sep …See details»
Glycostem Therapeutics - LinkedIn
Glycostem Therapeutics is a biotech company that develops Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. See their website, employees, updates, and publications ...See details»
Glycostem - Overview, News & Similar companies | ZoomInfo.com
May 13, 2022 Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem's lead product - oNKord® OSS, Netherlands, …See details»
Glycostem Therapeutics B.V. - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Glycostem …See details»
Glycostem Company Profile - Office Locations, Competitors ... - Craft
Glycostem is a company specializing in allogeneic cellular immunotherapy. It uses allogeneic cells like Natural Killer (NK) cells for the treatment of leukemia, lymphoma, and solid tumors. The …See details»
Glycostem Therapeutics - Contacts, Employees, Board Members, …
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells. Search Crunchbase. Start Free Trial . Chrome …See details»
Glycostem and Ghent University sign license agreement on NK cell ...
Dec 17, 2020 /PRNewswire/ -- Glycostem Therapeutics B.V., ... Our organization is dedicated to research and innovation with over 5,500 researchers active in a wide area of life, physical and …See details»
Glycostem and medac enter into license, manufacturing, supply …
Aug 1, 2022 Glycostem's lead product, oNKord ®, is manufactured from allogeneic raw material and is available off-the shelf. Thanks to its nine patent families, longstanding technical …See details»
Glycostem - media.nature.com
Glycostem’s biobank and shipped to any patient anywhere in the world, or held in hospitals. Glycostem is open to developing collaborations and has a strategy that enables partnerships …See details»
Glycostem launches pivotal oncology trial with evolved naked …
Glycostem is a clinical-stage company that develops naked NK cell therapies for acute myeloid leukemia (AML) and chimeric antigen receptor (CAR)-NK products for solid tumors. It has a …See details»
Zelluna Immunotherapy and Glycostem Ther... - Zelluna …
Oslo and Oss, Norway and the Netherlands, November 19, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products …See details»
Natural killer cells making better cancer immunotherapies
Glycostem also plans to initiate a clinical trial of oNKord in solid tumors in 2020. The basket trial will dose patients with NK cells every 3 weeks. The repeat dosing schedule is made possible bySee details»
Natural killer cells making better cancer immunotherapies
Glycostem is a biotech company that develops and produces natural killer (NK) cells for oncology indications. It offers off-the-shelf NK cell products, such as oNKord, and plans to expand into …See details»
Taking cellular immunotherapy to the next level - glycostem
Glycostem raises €14 million in equity Sep ’19 Glycostem raises €5 million for clinical trials 25th June ’19 Glycostem receives GMP license Glycostem Therapeutics B.V. Kloosterstraat 9, …See details»
Bulk and single-cell transcriptomics identify gene signatures of …
Glycostem Therapeutics leverages cord blood-derived HSCs to generate off-the-shelf therapeutic GTA002 NK cells. ... were strongly associated with the cell-cycle process, such as mitotic …See details»
Science and Technology - glycostem
Glycostem presented three posters demonstrating our novel NK cell therapeutics at the 19th Meeting of the Society for Natural Immunity (NK2022). Click on the links below to download …See details»
Production - glycostem
Glycostem has translated the natural process of differentiation of blood building stem cells to Natural Killer (NK) cells into a clinical scale and clinical grade NK cell production method. Off …See details»